Krystal Biotech has successfully transitioned from an early-stage research enterprise into a highly profitable, commercial-stage biotechnology company. Driven by the strong global commercial adoption and robust unit economics of its flagship product, VYJUVEK, the company generates substantial positive net income and impressive gross profit margins, frequently exceeding ninety percent on product sales. Financial results show consistent multi-million-dollar quarterly net incomes, reflecting strong U.S. demand, expanding international reimbursement approvals, and strict operational discipline. Unlike many early-stage biotechnology firms that operate at a perpetual net loss while funding clinical pipelines through external capital raises, Krystal utilizes its robust organic cash flows to self-fund its extensive research and development pipeline across dermatology, ophthalmology, and respiratory indications.